Intranasal corticosteroids: the development of a drug delivery device for fluticasone furoate as a potential step toward improved compliance
Devices for the aqueous delivery of intranasal corticosteroids to patients with allergic rhinitis have been available since 1984, so there is a need for new devices to be developed to provide ease of use, efficacy and safety. A novel drug delivery system has been developed for fluticasone furoate (F...
Gespeichert in:
| Veröffentlicht in: | Expert opinion on drug delivery 2007-11, Vol.4 (6), p.689-701 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 701 |
|---|---|
| container_issue | 6 |
| container_start_page | 689 |
| container_title | Expert opinion on drug delivery |
| container_volume | 4 |
| creator | Berger, William E Godfrey, James W Slater, Anna L |
| description | Devices for the aqueous delivery of intranasal corticosteroids to patients with allergic rhinitis have been available since 1984, so there is a need for new devices to be developed to provide ease of use, efficacy and safety. A novel drug delivery system has been developed for fluticasone furoate (FF; GlaxoSmithKline): a new enhanced-affinity glucocorticoid with a scent-free formulation. The FF system was developed, giving attention to patients' unmet needs, in order to promote acceptance and compliance. It demonstrates a number of key features including its ergonomic design, side-actuation system and short delivery nozzle. Exploiting issues with present devices highlighted the need for the FF system. This review reports data from key studies and surveys conducted by GlaxoSmithKline during development, to determine ease of use and acceptance of the FF system. Findings suggest that the FF system should aid in improving attitudes to the use of intranasal corticosteroids amongst physicians and patients. |
| doi_str_mv | 10.1517/17425247.4.6.689 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_17970670</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20359414</sourcerecordid><originalsourceid>FETCH-LOGICAL-c497t-ab1312786fb9062ea6315ca64ca098edd5a279a62508bd7895fdcb4f32c7de883</originalsourceid><addsrcrecordid>eNqFUU1v1DAQjRCIlsKdE_KJWxY7cey4nFAFpVIlLnC2JvaEdeXEwXa22v_Aj663uwhxAE4ez7yP0byqes3ohnVMvmOSN13D5YZvxEb06kl1Xlq8lp1qnz7WTX2Yn1UvUrqjtBWSsufVGZNK0lKfVz9v5hxhhgSemBCzMyFljMHZdEnyFonFHfqwTDhnEkYCxMb1e-l6t8O4P4ydQTKGSEa_FjqkMJf_GgNkJJAKYwm5sF1xKNILyeEeoiVuWmLYoS220-IdzAZfVs9G8Alfnd6L6tunj1-vPte3X65vrj7c1oYrmWsYWMsa2YtxUFQ0CKJlnQHBDVDVo7UdNFKBaDraD1b2qhutGfjYNkZa7Pv2onp71C0b_FgxZT25ZNB7mDGsSYued7zrm_8CG9p2ijNegPQINDGkFHHUS3QTxL1mVB-i0r-i0lyLYqAK5c1Jex0mtL8Jp2wK4P0R4OZy3gnuQ_RWZ9j7EMeSmXFJt_-Qv_yDvUXweWsgor4La5zLff--2wNaYbh2</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20359414</pqid></control><display><type>article</type><title>Intranasal corticosteroids: the development of a drug delivery device for fluticasone furoate as a potential step toward improved compliance</title><source>MEDLINE</source><source>Taylor & Francis Medical Library - CRKN</source><source>Taylor & Francis Journals Complete</source><creator>Berger, William E ; Godfrey, James W ; Slater, Anna L</creator><creatorcontrib>Berger, William E ; Godfrey, James W ; Slater, Anna L</creatorcontrib><description>Devices for the aqueous delivery of intranasal corticosteroids to patients with allergic rhinitis have been available since 1984, so there is a need for new devices to be developed to provide ease of use, efficacy and safety. A novel drug delivery system has been developed for fluticasone furoate (FF; GlaxoSmithKline): a new enhanced-affinity glucocorticoid with a scent-free formulation. The FF system was developed, giving attention to patients' unmet needs, in order to promote acceptance and compliance. It demonstrates a number of key features including its ergonomic design, side-actuation system and short delivery nozzle. Exploiting issues with present devices highlighted the need for the FF system. This review reports data from key studies and surveys conducted by GlaxoSmithKline during development, to determine ease of use and acceptance of the FF system. Findings suggest that the FF system should aid in improving attitudes to the use of intranasal corticosteroids amongst physicians and patients.</description><identifier>ISSN: 1742-5247</identifier><identifier>EISSN: 1744-7593</identifier><identifier>EISSN: 1743-5247</identifier><identifier>DOI: 10.1517/17425247.4.6.689</identifier><identifier>PMID: 17970670</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject>Administration, Intranasal ; Adrenal Cortex Hormones - administration & dosage ; Adrenal Cortex Hormones - therapeutic use ; allergic rhinitis ; Androstadienes - administration & dosage ; Androstadienes - therapeutic use ; Anti-Allergic Agents - administration & dosage ; Anti-Allergic Agents - therapeutic use ; Drug Delivery Systems - instrumentation ; Drug Delivery Systems - methods ; Drug Delivery Systems - psychology ; ergonomic design ; fine mist ; Humans ; intranasal corticosteroids ; nasal drug delivery ; Patient Compliance ; Rhinitis, Allergic, Perennial - drug therapy ; Rhinitis, Allergic, Seasonal - drug therapy ; sensory attributes ; short delivery nozzle ; side-actuated mechanism</subject><ispartof>Expert opinion on drug delivery, 2007-11, Vol.4 (6), p.689-701</ispartof><rights>Informa UK Ltd 2007</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c497t-ab1312786fb9062ea6315ca64ca098edd5a279a62508bd7895fdcb4f32c7de883</citedby><cites>FETCH-LOGICAL-c497t-ab1312786fb9062ea6315ca64ca098edd5a279a62508bd7895fdcb4f32c7de883</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1517/17425247.4.6.689$$EPDF$$P50$$Ginformahealthcare$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1517/17425247.4.6.689$$EHTML$$P50$$Ginformahealthcare$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,59623,59729,60412,60518,61197,61232,61378,61413</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17970670$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Berger, William E</creatorcontrib><creatorcontrib>Godfrey, James W</creatorcontrib><creatorcontrib>Slater, Anna L</creatorcontrib><title>Intranasal corticosteroids: the development of a drug delivery device for fluticasone furoate as a potential step toward improved compliance</title><title>Expert opinion on drug delivery</title><addtitle>Expert Opin Drug Deliv</addtitle><description>Devices for the aqueous delivery of intranasal corticosteroids to patients with allergic rhinitis have been available since 1984, so there is a need for new devices to be developed to provide ease of use, efficacy and safety. A novel drug delivery system has been developed for fluticasone furoate (FF; GlaxoSmithKline): a new enhanced-affinity glucocorticoid with a scent-free formulation. The FF system was developed, giving attention to patients' unmet needs, in order to promote acceptance and compliance. It demonstrates a number of key features including its ergonomic design, side-actuation system and short delivery nozzle. Exploiting issues with present devices highlighted the need for the FF system. This review reports data from key studies and surveys conducted by GlaxoSmithKline during development, to determine ease of use and acceptance of the FF system. Findings suggest that the FF system should aid in improving attitudes to the use of intranasal corticosteroids amongst physicians and patients.</description><subject>Administration, Intranasal</subject><subject>Adrenal Cortex Hormones - administration & dosage</subject><subject>Adrenal Cortex Hormones - therapeutic use</subject><subject>allergic rhinitis</subject><subject>Androstadienes - administration & dosage</subject><subject>Androstadienes - therapeutic use</subject><subject>Anti-Allergic Agents - administration & dosage</subject><subject>Anti-Allergic Agents - therapeutic use</subject><subject>Drug Delivery Systems - instrumentation</subject><subject>Drug Delivery Systems - methods</subject><subject>Drug Delivery Systems - psychology</subject><subject>ergonomic design</subject><subject>fine mist</subject><subject>Humans</subject><subject>intranasal corticosteroids</subject><subject>nasal drug delivery</subject><subject>Patient Compliance</subject><subject>Rhinitis, Allergic, Perennial - drug therapy</subject><subject>Rhinitis, Allergic, Seasonal - drug therapy</subject><subject>sensory attributes</subject><subject>short delivery nozzle</subject><subject>side-actuated mechanism</subject><issn>1742-5247</issn><issn>1744-7593</issn><issn>1743-5247</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUU1v1DAQjRCIlsKdE_KJWxY7cey4nFAFpVIlLnC2JvaEdeXEwXa22v_Aj663uwhxAE4ez7yP0byqes3ohnVMvmOSN13D5YZvxEb06kl1Xlq8lp1qnz7WTX2Yn1UvUrqjtBWSsufVGZNK0lKfVz9v5hxhhgSemBCzMyFljMHZdEnyFonFHfqwTDhnEkYCxMb1e-l6t8O4P4ydQTKGSEa_FjqkMJf_GgNkJJAKYwm5sF1xKNILyeEeoiVuWmLYoS220-IdzAZfVs9G8Alfnd6L6tunj1-vPte3X65vrj7c1oYrmWsYWMsa2YtxUFQ0CKJlnQHBDVDVo7UdNFKBaDraD1b2qhutGfjYNkZa7Pv2onp71C0b_FgxZT25ZNB7mDGsSYued7zrm_8CG9p2ijNegPQINDGkFHHUS3QTxL1mVB-i0r-i0lyLYqAK5c1Jex0mtL8Jp2wK4P0R4OZy3gnuQ_RWZ9j7EMeSmXFJt_-Qv_yDvUXweWsgor4La5zLff--2wNaYbh2</recordid><startdate>20071101</startdate><enddate>20071101</enddate><creator>Berger, William E</creator><creator>Godfrey, James W</creator><creator>Slater, Anna L</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20071101</creationdate><title>Intranasal corticosteroids: the development of a drug delivery device for fluticasone furoate as a potential step toward improved compliance</title><author>Berger, William E ; Godfrey, James W ; Slater, Anna L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c497t-ab1312786fb9062ea6315ca64ca098edd5a279a62508bd7895fdcb4f32c7de883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Administration, Intranasal</topic><topic>Adrenal Cortex Hormones - administration & dosage</topic><topic>Adrenal Cortex Hormones - therapeutic use</topic><topic>allergic rhinitis</topic><topic>Androstadienes - administration & dosage</topic><topic>Androstadienes - therapeutic use</topic><topic>Anti-Allergic Agents - administration & dosage</topic><topic>Anti-Allergic Agents - therapeutic use</topic><topic>Drug Delivery Systems - instrumentation</topic><topic>Drug Delivery Systems - methods</topic><topic>Drug Delivery Systems - psychology</topic><topic>ergonomic design</topic><topic>fine mist</topic><topic>Humans</topic><topic>intranasal corticosteroids</topic><topic>nasal drug delivery</topic><topic>Patient Compliance</topic><topic>Rhinitis, Allergic, Perennial - drug therapy</topic><topic>Rhinitis, Allergic, Seasonal - drug therapy</topic><topic>sensory attributes</topic><topic>short delivery nozzle</topic><topic>side-actuated mechanism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Berger, William E</creatorcontrib><creatorcontrib>Godfrey, James W</creatorcontrib><creatorcontrib>Slater, Anna L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Expert opinion on drug delivery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Berger, William E</au><au>Godfrey, James W</au><au>Slater, Anna L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intranasal corticosteroids: the development of a drug delivery device for fluticasone furoate as a potential step toward improved compliance</atitle><jtitle>Expert opinion on drug delivery</jtitle><addtitle>Expert Opin Drug Deliv</addtitle><date>2007-11-01</date><risdate>2007</risdate><volume>4</volume><issue>6</issue><spage>689</spage><epage>701</epage><pages>689-701</pages><issn>1742-5247</issn><eissn>1744-7593</eissn><eissn>1743-5247</eissn><abstract>Devices for the aqueous delivery of intranasal corticosteroids to patients with allergic rhinitis have been available since 1984, so there is a need for new devices to be developed to provide ease of use, efficacy and safety. A novel drug delivery system has been developed for fluticasone furoate (FF; GlaxoSmithKline): a new enhanced-affinity glucocorticoid with a scent-free formulation. The FF system was developed, giving attention to patients' unmet needs, in order to promote acceptance and compliance. It demonstrates a number of key features including its ergonomic design, side-actuation system and short delivery nozzle. Exploiting issues with present devices highlighted the need for the FF system. This review reports data from key studies and surveys conducted by GlaxoSmithKline during development, to determine ease of use and acceptance of the FF system. Findings suggest that the FF system should aid in improving attitudes to the use of intranasal corticosteroids amongst physicians and patients.</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>17970670</pmid><doi>10.1517/17425247.4.6.689</doi><tpages>13</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1742-5247 |
| ispartof | Expert opinion on drug delivery, 2007-11, Vol.4 (6), p.689-701 |
| issn | 1742-5247 1744-7593 1743-5247 |
| language | eng |
| recordid | cdi_pubmed_primary_17970670 |
| source | MEDLINE; Taylor & Francis Medical Library - CRKN; Taylor & Francis Journals Complete |
| subjects | Administration, Intranasal Adrenal Cortex Hormones - administration & dosage Adrenal Cortex Hormones - therapeutic use allergic rhinitis Androstadienes - administration & dosage Androstadienes - therapeutic use Anti-Allergic Agents - administration & dosage Anti-Allergic Agents - therapeutic use Drug Delivery Systems - instrumentation Drug Delivery Systems - methods Drug Delivery Systems - psychology ergonomic design fine mist Humans intranasal corticosteroids nasal drug delivery Patient Compliance Rhinitis, Allergic, Perennial - drug therapy Rhinitis, Allergic, Seasonal - drug therapy sensory attributes short delivery nozzle side-actuated mechanism |
| title | Intranasal corticosteroids: the development of a drug delivery device for fluticasone furoate as a potential step toward improved compliance |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T10%3A55%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intranasal%20corticosteroids:%20the%20development%20of%20a%20drug%20delivery%20device%20for%20fluticasone%20furoate%20as%20a%20potential%20step%20toward%20improved%20compliance&rft.jtitle=Expert%20opinion%20on%20drug%20delivery&rft.au=Berger,%20William%20E&rft.date=2007-11-01&rft.volume=4&rft.issue=6&rft.spage=689&rft.epage=701&rft.pages=689-701&rft.issn=1742-5247&rft.eissn=1744-7593&rft_id=info:doi/10.1517/17425247.4.6.689&rft_dat=%3Cproquest_pubme%3E20359414%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20359414&rft_id=info:pmid/17970670&rfr_iscdi=true |